Genentech/Xoma Raptiva Phase II Psoriatic Arthritis Trial Fails To Show Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
The study did not reach statistical significance after 12 weeks of therapy. The preliminary results show that 28% of Raptiva patients achieved an ACR 20 response compared with 19% of patients on placebo.